(C) Pharmaceutical Executive

INCHEON, South Korea — Celltrion is aggressively pivoting toward the global metabolic disease market, valued at over $100 billion, by deploying a sophisticated "two-track" strategy. The South Korean biopharmaceutical giant aims to secure a dominant position by simultaneously advancing chemical-based composite treatments for diabetes and next-generation biological innovations for obesity.

Phase 1 Clinical Trials Begin for Diabetes Composite 'CT-L03'
According to industry sources on April 8, 2026, Celltrion has officially commenced Phase 1 clinical trials for CT-L03, a candidate for the treatment of Type 2 diabetes, following approval from the Ministry of Food and Drug Safety (MFDS).

CT-L03 is a second-generation composite drug incorporating 4th-generation components, including SGLT-2 (sodium-glucose cotransporter-2) inhibitors. By combining two distinct active pharmaceutical ingredients (APIs) into a single tablet, Celltrion seeks to maximize patient compliance and convenience—a critical factor in chronic disease management.

The Phase 1 trial is being conducted at H+ Yangji Hospital in collaboration with DT&C CRO. The study involves 48 healthy adults and utilizes a crossover design to compare the pharmacokinetic (PK) characteristics and safety of the composite drug against the co-administration of individual components.

The strategic advantage of this "chemical track" lies in its speed to market. Under regulatory guidelines, if a composite drug demonstrates bioequivalence (identical absorption rates) to the separate administration of its components, it can bypass long-term clinical trials and proceed directly to a New Drug Application (NDA). With the study expected to conclude by August 2025, CT-L03 is poised to become a vital "cash cow" for the company’s metabolic portfolio.

Pioneering 4th-Generation Obesity Treatments
While the chemical track focuses on immediate market entry, the "biological track" targets long-term innovation in the high-growth obesity sector. Chairman Jung-jin Seo recently emphasized the company's commitment during a regular shareholders' meeting, revealing three 4th-generation obesity treatment candidates currently under development.

Celltrion’s obesity pipeline aims to differentiate itself from existing GLP-1 agonists by addressing a major clinical limitation: muscle loss. The company’s candidates are designed to ensure uniform weight loss while minimizing the depletion of lean muscle mass. Celltrion plans to begin animal testing for regulatory approval this May, with a goal of entering Phase 1 human clinical trials by 2027.

Massive Infrastructure Expansion to Support Global Ambitions
To support this massive pipeline expansion, Celltrion is undertaking a monumental upgrade of its production infrastructure. The company has announced an investment of approximately 1.23 trillion KRW ($910 million) to expand Plants 4 and 5 at its Songdo Campus in Incheon.

Once completed, Celltrion’s total production capacity will soar to 571,000 liters. This expansion will elevate the company to the world’s third-largest Contract Development and Manufacturing Organization (CDMO) in terms of drug substance (DS) production capacity, trailing only Samsung Biologics and Lonza.

Market Outlook: A $150 Billion Horizon
The urgency behind Celltrion’s strategy is fueled by the explosive growth of the metabolic disease market. According to Future Market Insights, the global market for obesity and diabetes treatments reached approximately $59.9 billion last year. The sector is projected to grow at an annual rate of 5.6%, reaching a staggering $103.3 billion (approx. 155 trillion KRW) by 2035.

"Our 4th-generation obesity treatment is characterized by its ability to maintain consistent efficacy while reducing muscle loss," a Celltrion official stated. "While we cannot disclose further specifics on CT-L03 at this stage, we are focused on proving equivalence to accelerate its commercialization."

By leveraging its expertise in both chemical synthesis and advanced biologics, Celltrion is not just expanding its portfolio—it is redefining its identity as a comprehensive global leader in metabolic health.